Results 111 to 120 of about 180,170 (299)

Flow cytometry‐based monitoring of chimeric antigen receptor (CAR) T cells: Reagent selection, assay design, and clinical utility

Cytometry Part B: Clinical Cytometry, EarlyView.
Abstract Accurate quantification of chimeric antigen receptor (CAR) T cells is essential for monitoring post‐infusion CART expansion and persistence and for real‐time clinical decision‐making. Multiparameter flow cytometry (MFC) enables rapid, live‐cell detection with absolute quantification and concurrent immunophenotypic characterization. This review
Jianhua Ling, Wei Wang, Sa A. Wang
wiley   +1 more source

Real-World Data of Light Chain (AL) Amyloidosis: Prognostic Indices and Treatment Patterns

Biomedicines
Background: Limited real-world data (RWD) may provide important information regarding diagnostic and treatment patterns in patients (pts) with AL Amyloidosis. The aim was to analyze the characteristics, treatment approach and clinical outcome of patients
Marko Mitrovic, Aleksandra Sretenovic, Natalija Kecman, Nikola Vukosavljevic, Maja Perunicic Jovanovic, Dragana Sobic Saranovic, Ruzica Maksimovic, Zoran Bukumiric, Danijela Lekovic, Arsen Ristic, Milena Todorovic Balint, Jelena Bila   +11 more
doaj   +1 more source

Prevalence of transthyretin cardiac amyloidosis in undifferentiated heart failure with preserved ejection fraction

ESC Heart Failure, Volume 12, Issue 2, Page 1176-1182, April 2025.
Abstract Aims Transthyretin amyloid cardiomyopathy (ATTR‐CM) is an increasinglyrecognized cause of heart failure with preserved ejection fraction (HFpEF), which may be diagnosed non‐invasively using 99mTc 3,3‐diphosphono‐1,2‐propanodicarboxylic acid (DPD) scintigraphy‐based diagnostic criteria.
L. Healy, G. Giblin, A. Gray, N. Starr, L. Murphy, D. O'Sullivan, E. Kavanagh, C. Howley, C. Tracey, E. Morrin, A. McDaid, A. Clarke, J.O. O'Neill, E. Joyce, M. O'Connell, N. G. Mahon   +15 more
wiley   +1 more source

Recent advances in the pharmacotherapy of multiple myeloma [PDF]

Multiple myeloma, a complex hematologic malignancy, has witnessed transformative advancements in pharmacotherapy. The thesis comprehensively explores the current landscape of advanced pharmacotherapy, delving into conventional and novel treatment ...
Sung, Wan Ting
core  

Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study. [PDF]

, 2010
BACKGROUND: Thalidomide plus dexamethasone (TD) is a standard induction therapy for myeloma. We aimed to assess the efficacy and safety of addition of bortezomib to TD (VTD) versus TD alone as induction therapy before, and consolidation therapy after ...
Gimema, Italian Myeloma Network, RUSSO, Domenico, Cavo M, Tacchetti P   +2 more
core  

Daratumumab induces CD38 internalization and impairs myeloma cell adhesion

OncoImmunology, 2018
Daratumumab (Dara), a human immunoglobulin G1 kappa (IgG1κ) monoclonal anti-CD38 antibody, has been approved by the U.S. Food and Drug Administration for the treatment of relapsed multiple myeloma (MM) as a single agent as well as in combination with ...
Jayeeta Ghose, Domenico Viola, Cesar Terrazas, Enrico Caserta, Estelle Troadec, Jihane Khalife, Emine Gulsen Gunes, James Sanchez, Tinisha McDonald, Guido Marcucci, Balveen Kaur, Michael Rosenzweig, Jonathan Keats, Steven Rosen, Amrita Krishnan, Abhay R Satoskar, Craig C Hofmeister, Flavia Pichiorri   +17 more
doaj   +1 more source

Longitudinal Swallowing and Salivary Changes With CLR 131 and Re‐Irradiation in Recurrent Head and Neck Cancer

Head &Neck, EarlyView.
ABSTRACT Background Patients with recurrent head and neck cancer (HNC) often present with severe, persistent dysphagia and xerostomia following prior chemoradiation. Although swallowing impairments and salivary dysfunction have been reported in this population, prior longitudinal studies have not examined changes in salivary composition or how these ...
Jenni Wu, Sara Gustafson, Meredith Hyun, Roxana Alexandridis, Mark Nicosia, Timothy McCulloch, Justine Bruce, Randall Kimple, Nicole Rogus‐Pulia   +8 more
wiley   +1 more source

Combining antigen-specific T cells with T-cell engager therapy induces a molecular signature that favors T-cell fitness

Blood Immunology & Cellular Therapy
: Both adoptive cellular therapy with tumor antigen–specific T cells and redirection of endogenous T cells with bispecific tumor-specific T-cell engaging antibodies rely on CD8+ T cell effector function. The two approaches use complementary mechanisms of
Manpreet Bariana, Sidharth Anand, Mark Batistick, Elena Cassella, Shaina A. Anuncio, Ariel Aptekmann, David S. Siegel, Mathias Oelke, Sojung Kim, Ruipeng Wang, Jack A. Ragheb, Johannes L. Zakrzewski   +11 more
doaj   +1 more source

Targeted treatments for multiple myeloma: specific role of carfilzomib [PDF]

, 2015
Dhivya Sugumar,1 Jesse Keller,2 Ravi Vij2 1Department of Internal Medicine, St Mary’s Health Center, 2Department of Medicine, Division of Oncology, Washington University in St Louis, St Louis, USA Abstract: Carfilzomib is a selective, irreversible
Sugumar D, Vij R, Keller J
core  

Early‐Life Exposures and Risk of Multiple Myeloma: A Population‐Based Case–Control Study in Australia

International Journal of Cancer, EarlyView.
Early‐life exposures may influence immune system development and, in turn, affect cancer susceptibility. In this population‐based case‐control study, the authors examined whether in utero or early childhood exposures were associated with the risk of developing multiple myeloma in adulthood.
Zhuoyu Sun, Julie K. Bassett, Simon Cheah, Fiona J. Bruinsma, Wendy Cozen, Simon J. Harrison, H. Miles Prince, Nicole Wong Doo, Graham G. Giles, Roger L. Milne, Brigid M. Lynch   +10 more
wiley   +1 more source